Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NERVthis companyMinerva Neurosciences, Inc.	$2.46	-0.12×	-0.24×	0×	-0.06×	-15.7%	0.0%	0.0%	0.0%	208.5%	-15.8%	-39708.5%	-0.46×	0.06×	0×	36.29×	0.0%	1	-24.23	2	C+
CVKDCadrenal Therapeutics, Inc. Common Stock	$0.99	-1.02×	4.94×	0×	-0.72×	66.0%	0.0%	0.0%	0.0%	-483.3%	-491.5%	-93.2%	0×	0.3×	0×	2.72×	0.0%	2	-15.68	2	C+
NRXSNeurAxis, Inc.	$6.27	-4.78×	12.13×	11.55×	-4.79×	-170.9%	84.2%	-219.4%	-218.5%	-229.5%	-204.7%	-15.7%	0.12×	0.59×	-105.85×	2.05×	0.0%	3	5	1	C-
RLYBRallybio Corporation	$15.71	-3.45×	0.53×	36.02×	0.01×	-35.3%	89.3%	-3270.9%	-1046.4%	-15.5%	-48.3%	-96.5%	0×	1.12×	0×	14.5×	0.0%	6	13.79	4	A
TAOXTAO Synergies Inc.	$2.60	-0.42×	0.55×	40.61×	-0.74×	0.2%	100.0%	-3025.2%	-9609.2%	-131.2%	-37.7%	-52.7%	0×	0.61×	0×	13.99×	2.2%	2	-2.39	2	C+
XCURExicure, Inc.	$0.91	-6.86×	8.69×	0×	-5.97×	-65.3%	0.0%	0.0%	0.0%	-126.0%	-86.8%	-25.1%	0.04×	0.7×	-10,117×	1.19×	0.0%	1	-27.84	1	C-
Peer median	—	-3.45×	4.94×	11.55×	-0.74×	-35.3%	84.2%	-219.4%	-218.5%	-131.2%	-86.8%	-52.7%	0×	0.61×	0×	2.72×	0.0%	2	-2.39	2	—